Anastrozole

Anastrozole 是目前在国外临床研究中出现的一款新药或疗法，主要研究方向为Anatomic Stage III Breast Cancer AJCC v8、Anatomic Stage IV Breast Cancer AJCC v8、Locally Advanced Unresectable HER2-Negative Breast Carcinoma、Locally Advanced Unresectable Hormone Receptor-Positive Breast Carcinoma。下面汇总了它当前在全球正在招募患者的研究，以及中国患者可以走的申请途径。

正在招募患者的 Anastrozole 研究

• ETHAN - ET for Male BC

  II 期招募中美国NCT05501704

• SNF Platform Study of HR+/ HER2-advanced Breast Cancer

  II 期招募中中国NCT05594095

• Entinostat Plus Pyrotinib and Endocrine Therapy in Advanced Triple-Positive Breast Cancer After Trastuzumab Failure

  I 期 / II 期招募中中国NCT07708194

• Compare Adjuvant Monotherapy With Endocrine or Accelerated Partial Breast Irradiation After Lumpectomy

  II 期招募中美国NCT05472792

• Anastrazole, Fulvestrant & Abemaciclib for HR+HER2- Metastatic Breast Cancer

  II 期招募中美国NCT05524584

• Elacestrant for Treating ER+/HER2- Breast Cancer Patients With ctDNA Relapse (TREAT ctDNA)

  III 期招募中比利时Cyprus法国德国NCT05512364

• Combination of Abemaciclib and Endocrine Therapy in Hormone Receptor Positive HER2 Negative Locally Advanced or Metastatic Breast Cancer With Focus on Digital Side Effect Management

  IV 期招募中德国瑞士NCT05362760

• First-in-Human Study of Tersolisib (STX-478) as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advanced Solid Tumors

  I 期 / II 期招募中美国比利时法国德国NCT05768139

• De-Escalation of Breast Radiation Trial for Hormone Sensitive, HER-2 Negative, Oncotype Recurrence Score Less Than or Equal to 18 Breast Cancer (DEBRA)

  III 期招募中美国加拿大中国香港日本NCT04852887

• Adebrelimab Combined With Dalpiciclib and Standard Endocrine Therapy for HR+/HER2 - Advanced Breast Cancer

  II 期招募中中国NCT06149130

• Adjuvant Abemaciclib for Locoregional Recurrence of HR-positive, HER2-negative Breast Cancer (JCOG2313, AURA)

  III 期招募中日本NCT07190443

• Efficacy and Safety of Fluzoparib Combined With Adjuvant Endocrine Therapy for HR+/HER2- SNF3-subtype Early Breast Cancer (BCTOP-L-A01)

  III 期招募中中国NCT05891093

• ctDNA-Guided De-Escalation of Adjuvant Chemotherapy With Dalpiciclib in HR-Positive/HER2-Negative Breast Cancer

  II 期招募中中国NCT06970912

• Prototype DAA/TAA Vaccine Targeting MUC1 for Immune Interception and Prevention in Ductal Carcinoma In Situ

  I 期招募中美国NCT06218303

• A Study of Alisertib in Combination With Endocrine Therapy in Patients With HR-positive, HER2-negative Recurrent or Metastatic Breast Cancer

  II 期招募中美国Portugal西班牙NCT06369285

• Fovinaciclib Plus Aromatase Inhibitors and Dual HER2 Blockade in a Response-Adapted Neoadjuvant Strategy for HR-Positive/HER2-Positive Early Breast Cancer

  II 期招募中中国NCT07616427

• Safety and Efficacy of T-DXd vs. CDK4/6i-based ET as First-line Therapy of HR-positive and HER2-low/Ultralow Advanced Breast Cancer Patients Classified as Non-luminal Subtype

  II 期招募中奥地利比利时法国德国NCT06486883

• Reversing InGuinal Hernia Trial: The Evaluation of Sex Hormones to Reverse Inguinal Hernias in Males

  I 期招募中美国NCT07604272

• A Study of the Impact of Endocrine Therapy on Surgical Outcomes in People With Lobular Breast Cancer

  II 期招募中美国NCT07483307

• Saruparib (AZD5305) Plus Camizestrant or Plus Endocrine Therapy, Compared With CDK4/6 Inhibitor Plus Endocrine Therapy or Plus Camizestrant in HR-Positive, HER2-Negative (IHC 0, 1+, 2+/ ISH Non-amplified), BRCA1, BRCA2, or PALB2m Advanced Breast Cancer

  III 期招募中美国Argentina澳大利亚奥地利NCT06380751

• A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)

  III 期招募中美国Argentina澳大利亚比利时NCT07174336

• Dalpiciclib Combined With Aromatase Inhibitors and Olmesartan as the First-line Treatment for HR+/HER2- Advanced Breast Cancer

  II 期招募中中国NCT07810088

• A Study of Elacestrant Versus Standard Endocrine Therapy in Women and Men With ER+,HER2-, Early Breast Cancer With High Risk of Recurrence

  III 期招募中美国Argentina澳大利亚奥地利NCT06492616

• Sj-subway, a Predictor for the Recurrence of High-risk Hormone Receptor-positive Breast That is Sensitive to Extended Endocrine Therapy

  不适用招募中中国NCT04476485

本页信息整理自 ClinicalTrials.gov 公开登记数据，仅供参考，不构成医疗建议；是否适合使用该药物，请以专业医生和研究团队的意见为准。